| Literature DB >> 26957612 |
David S Ettinger1, Douglas E Wood2, Wallace Akerley3, Lyudmila A Bazhenova4, Hossein Borghaei5, David Ross Camidge6, Richard T Cheney7, Lucian R Chirieac8, Thomas A D'Amico9, Thomas J Dilling10, M Chris Dobelbower11, Ramaswamy Govindan12, Mark Hennon7, Leora Horn13, Thierry M Jahan14, Ritsuko Komaki15, Rudy P Lackner16, Michael Lanuti17, Rogerio Lilenbaum18, Jules Lin19, Billy W Loo20, Renato Martins12, Gregory A Otterson20, Jyoti D Patel21, Katherine M Pisters15, Karen Reckamp22, Gregory J Riely23, Steven E Schild24, Theresa A Shapiro1, Neelesh Sharma25, James Stevenson25, Scott J Swanson8, Kurt Tauer26, Stephen C Yang1, Kristina Gregory27, Miranda Hughes27.
Abstract
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26957612 DOI： 10.6004/jnccn.2016.0031
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908